LON:APTA

Aptamer Group Interim Earnings Results & Report

Aptamer Group logo
GBX 0.30 -0.02 (-6.77%)
As of 11/18/2026 12:16 PM Eastern

Aptamer Group reported Interim earnings on March 25, 2026. The company reported EPS of GBX 0.04.

Earnings Announcement Details

Quarter
Interim
Report Date
Time
Before Market Opens

Aptamer Group EPS Results

Actual EPS
GBX 0.04
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Aptamer Group Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Aptamer Group Interim Earnings FAQ

Aptamer Group (LON:APTA) reported earnings of GBX 0.04 per share for Interim. The report was announced on Wednesday, March 25, 2026.

Aptamer Group Earnings Headlines

My $247 scanner for $7
Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.tc pixel
Aptamer Group Regulatory News
Aptamer Group PLC
See More Aptamer Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aptamer Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aptamer Group and other key companies, straight to your email.

About Aptamer Group

Aptamer Group (LON:APTA) is a leading provider of aptamer selection services and developer of aptamer-based reagents for use in research, bioprocessing, diagnostic, and therapeutic applications. Headquartered in York, UK, the Company partners globally to deliver aptamer-based solutions that drive discovery and development across the life sciences. Aptamer Group has developed the proprietary Optimer® platform technology that drives three distinct businesses: Aptamer Solutions, Aptamer Diagnostics and Aptamer Therapeutics. Through the use of its Optimer platform the Company aims to enable new opportunities, including discovery and development partnerships for improved biologic drugs, and new applications, such as novel assays and targets, to accelerate discovery and improve current standard processes. For more information, visit: https://aptamergroup.com/

View Aptamer Group Profile